When Apple breaks sales records, its suppliers often see their biggest revenue surges. You're getting exposure to the companies directly benefiting from the iPhone 17's unprecedented success.
The demand shock is creating a powerful ripple effect through the entire technology ecosystem. These aren't just any tech stocks - they're the specific companies receiving massive production orders right now.
Professional analysts handpicked these suppliers based on their critical role in Apple's manufacturing process. Each company provides essential technologies that make the iPhone possible.
Apple's record-breaking iPhone 17 sales have created a massive demand shock rippling through the global technology supply chain. When Apple scales up production, its network of suppliers experiences substantial revenue growth from the surge in component orders. This presents a tactical investment opportunity to benefit from a major product cycle's success.
This group focuses on the upstream partners essential to Apple's manufacturing process - from semiconductor fabricators and equipment makers to assembly specialists. These companies provide critical technologies like advanced chips, camera modules, display components, and manufacturing services that make the iPhone possible.
Each company was handpicked by professional analysts based on their integral role in Apple's supply chain ecosystem. These aren't random technology stocks - they're the specific manufacturers, suppliers, and service providers that directly benefit when Apple's production orders surge following exceptional sales performance.
Apple's record-breaking iPhone 17 sales are creating a massive demand shock across its global supply chain. This theme focuses on the key component manufacturers and suppliers poised to benefit from the surge in production orders.
Summary data for 'The Apple Effect: Supply Chain Surge' basket
AAPL: $4.03T
TSM: $1.27T
ASML: $422.08B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
+6
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+2.96%
On average, analysts expect assets in this group to grow 2.96% over the next year.
13 of 16 assets in this group are rated Buy by professional analysts.
